The efficacy and safety analysis of oral <i>isavuconazole</i> therapy of invasive pulmonary aspergillosis

This retrospective study aimed to explore the efficacy and safety of oral isavuconazole in treating invasive pulmonary aspergillosis (IPA). Among 31 enrolled patients, 21 survived and 10 died by the 42-days follow-up. The mean hospitalization duration was 21.81 ± 8.03 days, with isavuconazole administered for a mean of 25.10 ± 12.87 days. Survivors received isavuconazole for significantly longer period than non-survivors (28.62 vs 17.70 days, <i>P</i> = 0.025). The time to initiation of isavuconazole was significantly shorter in survivors compared to non-survivors (7.86 vs 14.4 days, <i>P</i> = 0.013). Early initiation of treatment was significantly associated with a shorter hospital stay (16.33 vs 25.83 days, <i>P</i> < 0.001). No significant adverse effects were observed in laboratory parameters, and no patients discontinued treatment due to side effects. These findings suggest that early oral administration of isavuconazole may reduce mortality rates and shorten hospitalization duration in patients with IPA. The treatment demonstrated a favourable safety profile, with minimal adverse reactions.